Reported Friday, Vertex's Zimislecel Shows Durable Insulin Independence In 10 Of 12 Patients With Type 1 Diabetes, All Achieve ADA Glycemic Targets

+0.08% Post

Vertex Pharmaceuticals Incorporated

VRTX

0.00

Reported Friday, Vertex's Zimislecel Shows Durable Insulin Independence In 10 Of 12 Patients With Type 1 Diabetes, All Achieve ADA Glycemic Targets

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Repligen's (NASDAQ:RGEN) Earnings May Just Be The Starting Point

ProMIS Neurosciences Q3 EPS $(0.24), Inline

Wells Fargo Maintains Overweight on uniQure, Lowers Price Target to $60

Korro Bio Announces 34% Workforce Reduction To Extend Cash Runway Into Second Half Of 2027 To Provide Sufficient Capital To Deliver Clinical Data From KRRO-121; Estimates That It Will Incur One-time Restructuring Charges Of ~$2.4M

Inventiva Halts Trading Of Ordinary Shares On Euronext Paris Pending Allocation Confirmation And Pricing Of US Offering Of New ADSs

Pre-Bell Movers | NVVE Moves Higher by 126.4%; Here Are 20 Stocks Moving Premarket

Scotiabank Initiates Coverage On Gilead Sciences with Sector Outperform Rating, Announces Price Target of $140

Imunon Q3 EPS $(1.16) Beats $(1.80) Estimate